logo
Intelligence
Tracking
Tools
logo
Intelligence
Tracking
Tools

Lento Bio Raises $680,000 In Oversubscribed Seed Round Led By Ichor Life Sciences

Sep 06, 2022•over 3 years ago

Amount Raised

$680,000

Round Type

seed

PotsdamTherapeuticsBiotechnologyHealth Care

Description

POTSDAM, NY / September 6, 2022 / Lento Bio, Inc., a preclinical pharmaceutical company developing small-molecule therapeutics to restore ocular lens flexibility and near-vision in presbyopia patients, announced today they have raised $680,000 in funding during their recent oversubscribed seed round. Ichor Life Sciences is the lead investor for the round, providing $400,000 in funding to Lento Bio.

Company Information

Company

Lento Bio

Location

Main Street

Potsdam, Brandenburg, Germany

About

Lento Bio is an Ichor portfolio company developing small-molecule therapeutic treatments for degenerative aging disorders, focused initially on developing AGE-breaking therapeutic eyedrops for presbyopia. Lento Bio was founded in 2022 and is headquartered in Potsdam, N.Y. For more information go to lentobio.com.

Related People

2 contacts

Sign in to view contact details

Sign in to view contact details

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech